Ecotoxicological Assessment of Surfactant Pollution Using Pyrocystis lunula Bioluminescence
Abstract
Abstract Bioluminescence-based bioassays have emerged as sensitive tools for assessing the ecotoxicological effects of marine contaminants. Among marine microplankton, bioluminescent dinoflagellates offer ecologically relevant responses due to their position at the base of the food web and their sensitivity to membrane-active compounds. In this study, the toxic effects of the anionic surfactants linear alkylbenzene sulfonate (LAS) and sodium dodecyl sulfate (SDS), widely used in detergents and frequently detected in coastal waters, were evaluated using the bioluminescent dinoflagellate Pyrocystis lunula . Cultures in the stationary growth phase were exposed for 24 and 48 h to increasing concentrations of LAS (0.1–50.0 mg L⁻¹) and SDS (5–50.0 mg L⁻¹), following standardized ecotoxicological guidelines. Bioluminescence inhibition was quantified at the nocturnal emission peak using a Tecan Infinite® M200 Pro Luminometer, and complemented by cell density and viability assessments. LAS induced a clear concentration-dependent inhibition of bioluminescence, with an estimated IC₅₀ of 38.11 mg L⁻¹ after 24 h, while SDS exhibited higher toxicity, particularly at concentrations ≥ 25 mg L⁻¹. Combined exposure to LAS and SDS resulted in stronger inhibitory effects than single-compound treatments. Notably, bioluminescence proved more sensitive than cell density in detecting early sublethal effects, indicating disruptions in membrane integrity and metabolic activity prior to cell death.…
Read the paper
Related studies
- The Matrisome: In Silico Definition and In Vivo Characterization by Proteomics of Normal and Tumor Extracellular Matrices
- The Escherichia coli MG1655 in silico metabolic genotype: Its definition, characteristics, and capabilities
- In silico pharmacology for drug discovery: methods for virtual ligand screening and profiling
- In silico prediction of splice-altering single nucleotide variants in the human genome
- In silico clinical trials: how computer simulation will transform the biomedical industry
- In silico optimization of a guava antimicrobial peptide enables combinatorial exploration for peptide design
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.